1. Homepage
  2. Equities
  3. Mexico
  4. Mexican Stock Exchange
  5. Genomma Lab Internacional, S.A.B. de C.V.
  6. News
  7. Summary
    LAB B   MX01LA010006

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.

(LAB B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oramed Pharmaceuticals Inc. and Genomma Lab Internacional, S.A.B. de C.V. Announces Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

11/18/2021 | 07:40am EDT

Oramed Pharmaceuticals Inc. and Genomma Lab Internacional, S.A.B. de C.V. announced the formation of a 50/50 joint venture between Genomma Lab and Oramed's majority-owned subsidiary Oravax Medical Inc. to develop and commercialize Oravax's oral COVID-19 vaccine candidate in Mexico. Genomma Lab is expected to contribute resources to the joint venture's oral COVID-19 vaccine development, as well as clinical, regulatory, and commercial activities in Mexico supported by close strategic cooperation between the two companies. Genomma Lab will leverage its extensive supply chain capabilities, partnerships and market presence in Latin America to support the business development process and vaccine roll-out throughout the region. To align interests and deepen the collaboration, Oramed and Genomma Lab announced their intention to enter into a USD 20 million share swap based on the average closing price of their respective shares during the past 15 trading days. Genomma Lab has also committed to participate in a future investment in Oravax.


ę S&P Capital IQ 2021
All news about GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
04/28TRANSCRIPT : Genomma Lab Internacional, S.A.B. de C.V., Q1 2022 Earnings Call, Apr 28, 202..
CI
04/27Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarte..
CI
04/27GENOMMA LAB INTERNACIONAL B DE C : Q1 2022 Earnings Release
PU
04/27GENOMMA LAB INTERNACIONAL B DE C : Application of IAS-36 and IFRS-13 (PIR) effects
PU
04/27GENOMMA LAB INTERNACIONAL B DE C : Aplicación de los efectos por IAS-36 e IFR-13 (PIR)
PU
04/19GENOMMA LAB INTERNACIONAL B DE C : 1Q-2022 Earnings Call Advisory
PU
04/15GENOMMA LAB INTERNACIONAL B DE C : PROXY 2022 – Genomma Lab informs the amount to be..
PU
04/15GENOMMA LAB INTERNACIONAL B DE C : PROXY 2022 – Genomma Lab informs the amount to be..
PU
04/15GENOMMA LAB INTERNACIONAL B DE C : PROXY 2022 – Genomma Lab informs the proposed ame..
PU
04/15GENOMMA LAB INTERNACIONAL B DE C : PROXY 2022 – Genomma Lab nominees for Board of Di..
PU
More news
Financials
Sales 2022 16 502 M 819 M 819 M
Net income 2022 2 108 M 105 M 105 M
Net Debt 2022 2 536 M 126 M 126 M
P/E ratio 2022 11,8x
Yield 2022 1,98%
Capitalization 19 402 M 963 M 963 M
EV / Sales 2022 1,33x
EV / Sales 2023 1,26x
Nbr of Employees 2 365
Free-Float 70,9%
Chart GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Duration : Period :
Genomma Lab Internacional, S.A.B. de C.V. Technical Analysis Chart | LAB B | MX01LA010006 | MarketScreener
Technical analysis trends GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 19,21 MXN
Average target price 25,85 MXN
Spread / Average Target 34,6%
EPS Revisions
Managers and Directors
Jorge Luis Brake Valderrama Chief Executive Officer
Antonio Zamora Galland Vice President-Administration & Finance
Rodrigo Alonso Herrera Aspra Chairman
Marco Sparvieri Chief Operating Officer & Executive Vice President
Juan Alonso Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.-10.57%963
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421